In a filing, Dyne Therapeutics Inc. revealed its insider Brumm Joshua T unloaded Company’s shares for reported $79866.0 on Sep 12. In the deal valued at $10.41 per share,7,672 shares were sold. As a result of this transaction, Brumm Joshua T now holds 245,711 shares worth roughly $ 2.42 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Farwell Wildon sold 1,707 shares, generating $17,770 in total proceeds. Upon selling the shares at $10.41, the Chief Medical Officer now owns 89,250 shares.
Before that, HIGH SUSANNA GATTI sold 1,635 shares. Dyne Therapeutics Inc. shares valued at $17,020 were divested by the Chief Operating Officer at a price of $10.41 per share. As a result of the transaction, HIGH SUSANNA GATTI now holds 107,216 shares, worth roughly $1.06 million.
Raymond James upgraded its Dyne Therapeutics Inc. [DYN] rating to a Strong buy from a an Outperform in a research note published on Monday, February 27, 2023; the price target was increased to $27 from $16. PT values the company’s stock at a premium of 63.52 to its Monday closing price.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc. [NASDAQ:DYN] saw its stock jump 6.37% to $9.85. On the same session, the stock had its day’s lowest price of $9.10, but rose to a high of $10.06. Over the last five days, the stock has lost -11.90%. Dyne Therapeutics Inc. shares have fallen nearly -15.01% since the year began. Nevertheless, the stocks have fallen -29.64% over the past one year. While a 52-week high of $15.60 was reached on 03/06/23, a 52-week low of $8.04 was recorded on 04/11/23. SMA at 50 days reached $11.05, while 200 days put it at $12.00. A total of 0.91 million shares were traded, compared to the trading of 1.24 million shares in the previous session.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 9.28, which if violated will result in even more drops to 8.71. On the upside, there is a resistance level at 10.24. A further resistance level may holdings at 10.63. The Relative Strength Index (RSI) on the 14-day chart is 39.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.16%. Stochastics %K at 24.25% indicates the stock is a holding.
How much short interest is there in Dyne Therapeutics Inc.?
A steep rise in short interest was recorded in Dyne Therapeutics Inc. stocks on Aug 30, 2023, growing by 0.44 million shares to a total of 5.63 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 5.19 million shares. There was a rise of 7.82%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 12.58% of the overall stock float, the days-to-cover ratio (short ratio) rose to 17.53.
Dyne Therapeutics Inc. [DYN] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 2,833,181 shares, or roughly 4.64% of the outstanding DYN shares. In other words, the investor’s shares have risen by 617,282 from its previous 13-F filing of 2215899.0. Additionally, Citadel Advisors LLC decreased -9.52% of its stake after which the total value it holdings stand at $30,848,434, while Deep Track Capital LP added 7.08% of its stake to hold $28.5 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 916,834 shares of Dyne Therapeutics Inc., while Wasatch Advisors, Inc. bought -667,743 shares. At present, Franklin Advisers, Inc. is holding 1,895,579 shares valued at $21.61 million. Goldman Sachs & Co. LLC owned 1,879,615 shares of the company at the time of its most recent 13F filing, worth $21.43 million.
According to FactSet, Dyne Therapeutics Inc.’s share price will average $29.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 202.38 percent from its previous closing price of $9.26. Analysts expect Dyne Therapeutics Inc. stock to reach the higher price of $47.00, while the lowest price estimate is $20.00. However, 8 analysts have rated DYN stock as a Buy in their predictions for 2023.